Agilent and Oxford Gene Technology Expand Partnership
News Oct 18, 2011
Agilent Technologies Inc. and Oxford Gene Technology have announced that they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.
Mike Evans, chief executive of OGT, said: “We are delighted to have been able to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”
“Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program,” said Robert Schueren, vice president and general manager of Agilent’s genomics business.
Schueren continued, “OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”
SureSelect target enrichment has enabled researchers to identify mutations associated with more than 50 Mendelian diseases, 10 different types of cancer, and other complex ailments such as schizophrenia and Parkinson’s disease.
The SureSelect platform offers the most complete offering of catalog and custom capture kits (including comprehensive exome kits for human, mouse, and other model organisms, and flexible custom DNA or RNA target enrichment solutions) on all major next-generation sequencing platforms.
The initial agreement, announced in 2007, gave OGT access to Agilent’s microarray platform and appointed it an Agilent Certified Service Provider for microarrays.
In 2010, following the successful completion of the world’s largest copy number variation study, OGT was the first company to be awarded Agilent High-Throughput Microarray Certified Service Provider status.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018